#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcomanews2026-03-30T11:33:22+00:00March 30th, 2026|Endpoints News|
Kailera plans IPO for Phase 3 obesity drug from Hengruinews2026-03-29T23:05:55+00:00March 29th, 2026|Endpoints News|
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failurenews2026-03-29T16:00:49+00:00March 29th, 2026|Endpoints News|
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibodynews2026-03-28T21:24:57+00:00March 28th, 2026|Endpoints News|
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposurenews2026-03-28T16:00:08+00:00March 28th, 2026|Endpoints News|
A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and morenews2026-03-28T10:00:36+00:00March 28th, 2026|Endpoints News|
Otsuka buys Transcend Therapeutics for $700M upfrontnews2026-03-27T18:21:02+00:00March 27th, 2026|Endpoints News|
CHMP recommends subcutaneous form of Sanofi’s Sarclisa and four new drugsnews2026-03-27T17:29:48+00:00March 27th, 2026|Endpoints News|
AnaptysBio spins out biotech operations; Affibody’s data in hidradenitis suppurativanews2026-03-27T15:33:54+00:00March 27th, 2026|Endpoints News|
FDA approves Rocket’s gene therapy for ultra-rare immune diseasenews2026-03-27T15:13:30+00:00March 27th, 2026|Endpoints News|
